MyPharmaGenes® Brain PGx

MyPharmaGenes® Brain PGx is a comprehensive pharmacogenetic test for the definition of a personalized pharmacological plan. This test evaluates 68 drugs commonly used in Psychiatry and Neurology.

MyPharmaGenes® Brain PGx is supported by an interactive WebApp that helps the user manage their medications and register drugs that have triggered side effects.

At some point in one’s life, medication is highly likely to be necessary. Staying informed can help avoid potential side effects.

Why is it important to address Pharmacogenetics?

• Variability in drug response constitutes a major public health concern, accounting for 2.5–10.6% of all hospital admissions in the EU [1].
• More than 90% of the drugs are not effective for more than 50% of patients [2,3].
• Approximately 17% of patients are receiving a drug that triggers adverse reactions [4].
• Genetic variants affecting the absorption, distribution, metabolism, excretion, and toxicity of drugs explain around 20–30% of the variability in drug response between individuals [5].

MyPharmaGenes® BRAIN PGx is indicated for:

• Patients who are starting new therapies;
• Patients who are not achieving therapeutic goals and/or experience moderate to severe adverse effects with the current therapy.

What is analysed?

The MyPharmaGenes® Brain PGx test analyses genetic variants associated with the metabolism and response to certain drugs, scientifically validated and with proven clinical utility.

MyPharmaGenes® BRAIN PGx highlights:

• Coverage of 68 drugs;
• Evaluation of 20 genes and 70 genetic variants;
• Evaluation of CYP2D6 CNVs and hybrid structures.

Evaluation of CYP2D6 CNVs and hybrid structures is of high importance for the correct definition of a patient phenotype [6]. Without their analysis, the clinical recommendations presented may be misleading which may result in misguided patient care.

With the correct evaluation of the patients’ genotypic profile is possible to:

• Prescribe more adequate drug dosages;
• Evaluate the patient’s response to the treatment;
• Avoid adverse drug reactions;
• Select alternative agents, if necessary.

And, consequently, offer better treatment to more patients.

MYPHARMAGENES® BRAIN PGX PANEL

Drugs evaluated by therapeutic areA

International Guidelines and drug lABEL ANNOTATIONS

MyPharmaGenes® Brain PGx is in line with the recommendations provided by international pharmacogenetics consortia (CPIC, DPWG and CPNDS) that develop peer-reviewed gene-drug guidelines that are published and updated periodically based on new developments across several fields of medicine, as well as by several drug agencies (FDA, EMA, Health Canada, PMDA Japan and Swissmedic).

Scientific Studies